Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18632488 | 0.73 | POLB (0.34) | — | |
| SCHEMBL9788252 | 0.71 | — | — | |
| SCHEMBL8798449 | 0.70 | CYP2C19 (0.32) | CYP2C19 | |
| SCHEMBL2855195 | 0.67 | CYP1A2 (0.39) | CYP2C19 | |
| SCHEMBL1747425 | 0.65 | — | — | |
| SCHEMBL2733522 | 0.65 | — | — | |
| SCHEMBL22023035 | 0.65 | ACE (0.32) | — | |
| SCHEMBL10171750 | 0.65 | — | — | |
| SCHEMBL8282705 | 0.64 | IRAK4 (0.34) | — | |
| SCHEMBL625848 | 0.63 | MGAM (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114951-B9 | NOVEL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2015-09-02 | — | — | EP | disclosed |
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-8338431-B2 | Phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2012-12-25 | — | — | US | disclosed |
| US-8338431-B2 | Phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2012-12-25 | — | — | US | disclosed |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| US-20100099688-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2010-04-22 | — | — | US | disclosed |
| US-20100099688-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2010-04-22 | — | — | US | disclosed |
| EP-2114951-A2 | NOVEL PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008104175-A2 | NOVEL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099688-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS | PDE3A, PDE5A, PDE3B | CYP2C19 503/4885 |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | CXCR5, CXCR1, CCR5 | CYP2C19 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.